TRP_1170x120_3-8-19

Valeant Pharmaceuticals International

Valeant to sell iNova Pharmaceuticals for $930 million

Valeant to sell iNova Pharmaceuticals for $930 million

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to sell its iNova Pharmaceuticals unit for $930 million in cash to help pay down debt. Valeant said Thursday that iNova, whose portfolio includes prescription drugs and over-the-counter health products, is being sold to a company jointly owned by funds of Pacific Equity Partners and Carlyle Group LP.

L’Oréal buys CeraVe, AcneFree, Ambi brands from Valeant

L’Oréal buys CeraVe, AcneFree, Ambi brands from Valeant

CLICHY, N.Y., and LAVAL, Quebec — L’Oréal plans to acquire the CeraVe, AcneFree and Ambi skin care brands from Valeant Pharmaceuticals International Inc. for $1.3 billion in cash. Plans call for CeraVe, AcneFree and Ambi to become part of the L’Oréal Active Cosmetics Division, which includes the La Roche-Posay, Vichy and SkinCeuticals brands developed with

Zoetis executive joins Valeant as CFO

Zoetis executive joins Valeant as CFO

NEW YORK — Paul Herendeen has left Zoetis Inc. to become executive vice president of finance and chief financial officer at Valeant Pharmaceuticals International Inc. Valeant said Monday that Herendeen takes over the CFO role from Robert Rosiello, who has been appointed executive vice president of corporate development and strategy. “I am pleased to bring

Valeant makes changes to executive team

Valeant makes changes to executive team

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. has instituted a series of leadership and organizational changes, including an expansion of its executive committee and the duties of some senior executives. Valeant said Christina Ackermann has joined the company as executive vice president and general counsel of Valeant, succeeding Robert Chai-Onn, who will be leaving Valeant

WBA’s Gourlay: We’ll work with Valeant

WBA’s Gourlay: We’ll work with Valeant

During the Walgreens Boots Alliance’s conference call this week on its third-quarter results, co-COO Alex Gourlay told analysts that WBA will address Valeant Pharmaceuticals International’s concerns about its distribution arrangement with the company. Under the deal, announced in December, WBA and Valeant entered agreements in which the drug maker will directly distribute branded prescription drugs

Valeant names Perrigo’s Papa as chairman, CEO

Valeant names Perrigo’s Papa as chairman, CEO

NEW YORK — Joseph Papa has resigned as chairman and chief executive officer of Perrigo Co. plc to join Valeant Pharmaceuticals International Inc. as chairman and CEO. Valeant said Monday that Papa, 60, is slated to start at the company by early May. Papa will succeed J. Michael Pearson, who is expected to remain as

Mylan releases generic version of Ultram

Mylan releases generic version of Ultram

PITTSBURGH — Mylan N.V. has rolled out tramadol hydrochloride extended-release tablets, a chronic pain medication, in the United States. The drug maker said its product comes in dosages of 100 mg, 200 mg and 300 mg and is a generic version of Ultram ER tablets from Valeant Pharmaceuticals International. Tramadol hydrochloride ER tablets are indicated

Valeant starts search to replace CEO Pearson

Valeant starts search to replace CEO Pearson

LAVAL, Quebec — J. Michael Pearson is slated to step down as chief executive officer of Valeant Pharmaceuticals International Inc., which has begun a search for a new CEO. The embattled drug maker said Monday that its board has initiated a search to identify a candidate to take over for Pearson, who will continue to

Valeant appoints interim CEO

Valeant appoints interim CEO

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. has named former chief financial officer Howard Schiller as interim chief executive officer, effective immediately. Valeant said Wednesday that it appointed Schiller to the interim role because chairman and CEO J. Michael Pearson remains in the hospital, where he is being treated for severe pneumonia, and the timing

Walgreens, Valeant sign distribution pact

DEERFIELD, Ill. — Walgreens and Valeant Pharmaceuticals International Inc. have inked a distribution deal that will cut prices of Valeant prescription products at Walgreens by 10%, and may be extended to independent retail pharmacies. The discount will apply to wholesale list prices and will be phased in over the next six to nine months. The

Walgreens, Valeant plan direct distribution model

Walgreens, Valeant plan direct distribution model

LAVAL, Quebec, and DEERFIELD, Ill. — Valeant Pharmaceuticals International Inc. and Walgreens have entered agreements in which the drug maker will directly distribute branded prescription drugs in a range of therapeutical areas to the pharmacy chain at reduced pricing. Valeant said Monday that, under the fulfillment agreement, it will cut the wholesale list prices of